
|Articles|May 1, 2005
How to treat refractory OAB using injectable botulinum toxin
No patient has developed urinary retention or elevated post-void residuals following our modified injection technique.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











